Poster presentations (as of 10/4/23)

Poster Session C
Saturday, October 14 | 12:30 pm-4:00 pm
Level 2, Exhibit Hall D

C001: *Retrospective analysis of TROP2 expression in colorectal cancer (CRC) primary tumors and liver metastases (LM) and its correlation with clinical factors*. Robert W. Lentz, University of Colorado School of Medicine, Aurora, CO United States.

C002: *Identification of biomarkers predictive of sensitivity to the CHK1/2 inhibitor ACR-368 using high-resolution phosphoproteomics and development of an ACR-368-tailored patient responder identification 3-marker test, ACR-368 OncoSignature*. Caroline M. Wigerup, Acrivon AB, Lund, Sweden.

C003: *A Quantitative Mass Spectrometry Workflow for Highly Multiplexed Measurement of Immunomodulatory Proteins to Support Immunotherapy Clinical Trials*. Ons Ousji, CellCarta, Montreal, QC Canada.

C004: *Liquid biopsy based on the lipid profiles in plasma-derived extracellular vesicles which can be utilized for breast cancer diagnosis*. Masahiro Kawashima, Kyoto University, Kyoto, Japan.

C005: *TP53 Wildtype Status Can Predict Sensitivity to XPO1 Inhibitors in Patient-Derived Cancer Models*. Marie Maloof, Karyopharm Therapeutics, Newton, MA United States.

C006: *BID upregulation associates with sensitivity to TTK inhibitors in tumor cell lines*. Miguel A. Molina-Vila, Laboratory of Oncology, Pangaea Oncology, Dexeus University Hospital, Barcelona, Spain.

C007: *Improved T-cell and B-cell receptor repertoire profiling and immunophenotyping for biomarker discovery*. Alex Chenchik, Cellecta, Inc., Mountain View, CA United States.

C008: *Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cancer*. Yan Zhang, Eisai Inc., Nutley, NJ United States.

C009: *Biomarker analyses for predicting the benefit from immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer*. Mitsuo Osuga, Wakayama Medical University, Wakayama, Japan.

C010: *A Comprehensive Predictive Biomarker Analysis for MEK Inhibitors in Patient-derived Xenograft (PDX) Models*. Yanghui Sheng, Crown Bioscience, Suzhou, China (Mainland).

C012: *Exploring thrombospondin-1 variant and splicing factors as potential diagnostic biomarkers and therapeutic targets in thyroid cancer*. Seung Joon Baek, Seoul National University, Seoul, Korea, Republic of.

C013: *Clinical biomarkers based on PK/PD modeling to guide the development for a first-in-class, highly selective SMARCA2 (BRM) degrader, PRT3789*. Neha Bhagwat, Prelude Therapeutics, Inc., Wilmington, DE United States.

C014: *Pan-cancer Analysis Portrays NVL as a Diagnostic and Prognostic Biomarker*. Mousumi Datta, Gurunanak Institute of Pharmaceutical Science and Technology, Kolkata, India.

C015: *FGFR1 and RB1 Genetic Alteration Impair Clinical Benefit of CDK4/6 inhibitors plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer*. Jianxin Zhong, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China (Mainland).

C016: *Evaluating clinical biomarkers of FHD-286, a potent and selective inhibitor of BRG1/BRM, in metastatic uveal melanoma*. Jessica Wan, Foghorn Therapeutics, Cambridge, MA United States.

C017: *Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response*. Pieter Mestdagh, CellCarta, Antwerp, Belgium.

C018: *Prognostic worth of Nrf2/BACH1/HO-1 signals in the development of breast cancer*. Precious Barnes, University of Cape Coast, Cape Coast, Ghana.

C019: *Inactivating TSC1 and TSC2 alterations, co-mutations, and genomic instability in advanced cancers: Analysis of a real-world (RW) patient (pt) population using the Foundation Medicine genomic database*. David J. Kwiatkowski, Brigham and Women's Hospital, Boston, MA United States.

C020: *First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors*. Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY United States.

C022: *Phase 1 Study of BDTX-1535, an Oral 4th Generation Inhibitor, in Patients with Non-Small Cell Lung Cancer and Glioblastoma: Preliminary Dose Escalation Results*. Alex Spira, NEXT Oncology Virginia, Fairfax, VA United States.

C024: *Trial in progress: Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors*. Shivaani Kummar, Oregon Health and Science University, Portland, OR United States.

C025: *Trial in progress: First-in-human study of BBT-207 in advanced non-small cell lung cancer harboring EGFR mutation after treatement with EGFR TKI*. NaEun Jeon, Bridge Biotherapeutics, Inc., Seongnam-si, Korea, Republic of.

C026: *Initial Safety, Pharmacokinetics, and Recommended Phase 2 Dose from RAMP 203: A Phase 1/2 Study of Avutometinib + Sotorasib in KRAS G12C Mutant Non-Small Cell Lung Cancer*. Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA United States.

C027: *RSO-021, a first-in-class covalent inhibitor of mitochondrial PRX3: From bench to bedside*. George N. Naumov, RS Oncology LLC, Cambridge, MA United States.

C028: *A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors*. Benjamin Schlechter, Dana Farber Cancer Institute, Boston, MA United States.

C029: *Phase Ib/II open label, multi-arm, parallel cohort dose finding and expansion study of NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors or docetaxel in patients with lung cancer (NuTide:303)*. Richard H. Wilson, Beatson West of Scotland Cancer Centre/University of Glasgow, Glasgow, United Kingdom.

C030: *HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer*. Jonathan Riess, University of California Davis Comprehensive Cancer Center, Sacramento, CA United States.

C031: *A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer*. Susanna Ulahannan, University of Oklahoma Health Sciences Center, Oklahoma City, OK United States.

C032: *NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study*. Sarah P. Blagden, Early Phase Clinical Trials Unit, Churchill Hospital, University of Oxford, Oxford, United Kingdom.

C033: *Preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors*. Timothy Wyant, Aulos Bioscience, Larkspur, CA United States.

C034: *First in Human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors*. Nadeem Q. Mirza, Aprea Therapeutics, Inc., Doylestown, PA United States.

C035: *Chemotherapy plus HER2-targeted therapy versus endocrine therapy plus HER2-targeted therapy as first-line treatment in patients with HR+/HER2+advanced breast cancer: A real-world trial*. Yuehua Liang, Peking University Cancer Hospital, Beijing, China (Mainland).

C036: *A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer*. Helena Yu, Memorial Sloan-Kettering Cancer Center, New York, NY United States.

C037: *Largescale organoid panel drug screening to short-track clinically-relevant output*. Mariusz Madej, Crown Bioscience, Leiden, Netherlands.

C038: *High throughput application of the NanoBiT Biochemical Assay for the discovery of selective p110α isoform binders that block its interaction with KRAS*. Mohamed (Soly) Soliman Ismail, The Francis Crick Institute, London, United Kingdom.

C040: *Discovery and Development of Novel ATG13 Degrading Compounds that Inhibit Autophagy and Treat Non-Small Cell Lung Cancer*. Patrick M. Hagan, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA United States.

C041: *Drug repurposing to target TGF-β in chemoresistant high-grade serous ovarian cancer*. Michelle W.Y. Wong-Brown, University of Newcastle, Callaghan, Australia.

C042: *Integrative analyses of CRISPR and drug screens identify a selective and potent compound for oral squamous cell carcinoma*. Annie Wai Yeeng Chai, Cancer Research Malaysia, Subang Jaya, Malaysia.

C043: *Discovery of new drug combinations for metastatic colorectal cancer*. Eun-Jung In, WEHI, Parkville, VIC Australia.

C044: *Discovery and characterization of novel fragment binders of the VHR phosphatase as a drug target for cervix cancer*. Jiaqian Wu, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA United States.

C045: *Combinations of PI3K inhibitors with targeted oncology agents in multicellular spheroid models*. Thomas Dexheimer, Frederick National Laboratory for Cancer Research, Frederick, MD United States.

C046: *Rapid autopsy provides unique research opportunity to evaluate KRAS^{G12C} inhibitor resistance mechanisms in non-small cell lung cancer*. Hilal Ozakinci, Moffitt Cancer Center, Tampa, FL United States.

C047: *Comprehensive curation of label-free proteomics data for 186 patient-derived xenograft (PDX) models in HuBase™*. Hengyuan Liu, Crown Bioscience, Inc., Suzhou, China (Mainland).

C048: *Inducible activation of sgRNA libraries in tumor xenografts empowers large-scale in vivo target discovery screens*. Silvia Fenoglio, Tango Therapeutics, Boston, MA United States.

C049: *Copenhagen Prospective Personalized Oncology (CoPPO) – The utility of using genomic profiling for tailored therapy in a Phase 1 setting*. Laila Belcaid, Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

C050: *Comprehensive analysis of causes for unsuccessful genomic profiling in a Phase 1 setting*. Laila Belcaid, Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

C051: *Alteration of protein translation by eIF4A1 inhibition exquisitely primes lymphoma cells to induction of ferroptosis*. Paola Manara, University of Miami, Miami, FL United States.

C052: *Circumventing EGFR inhibitor resistance in NSCLC using transomics*. Christopher J. Nicholson, Pepper Bio, Cambridge, MA United States.

C053: *BACE1 cleaves EGFR to drive lung adenocarcinoma brain metastasis*. Shawn C. Chafe, McMaster University, Hamilton, ON Canada.

C054: *PARP16 modulates MYC expression and susceptibility of Ewing's Sarcoma cells to PARP1 inhibition*. Ou Deng, Moffitt Cancer Center, Tampa, FL United States.

C055: *Withaferin A offers novel targeted immunotherapy against high-grade serous ovarian carcinoma*. Jasmin C. Acosta, Rush University Medical Center, Chicago, IL United States.

C056: *Characterization of prostate cancer secretomes for therapeutic intervention*. Tarana Arman, Fred Hutchinson Cancer Center, Seattle, WA United States.

C057: *Fibrolamellar carcinoma single-nucleus RNA sequencing reveals alteration of mitochondrial energetic pathways*. Nihal Bharath, Boston Children's Hospital, Boston, MA United States.

C058: *Clinical relevance of telomerase upregulation via TERT promoter mutation or TERC amplification in high-grade ovarian cancer*. Felix Blanc-Durand, National University Singapore - Cancer Science Institute, Singapore, Singapore.

C059: *Probabilistic graph-based model uncovers druggable vulnerabilities in major solid cancers*. Stephanie T. Schmidt, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

C061: *GNL3 promotes prostate cancer growth by regulating androgen receptor protein stability*. Edwin Cheung, University of Macau, Taipa, Macao (Greater China).

C062: *Discovery and clinical evaluation of a potent and selective $A_{2A/2B}$ dual receptor antagonist*. Duane DeMong, Merck & Co. Inc., Boston, MA United States.

C063: *OSE279, a PD-1 blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preclinical characterization and early clinical results of a First-In-Human (FIH) study in subjects with advanced malignancies*. Philippe Cassier, Centre Léon Bérard, Lyon, France.

C064: *Combination of D3L-002, an anti-TIGIT/PVRIG bispecific antibody, with D3S-001, a KRAS G12C inhibitor, transformed tumor microenvironment from "cold" to "hot" and achieved durable tumor remission in preclinical models*. Tienan Wang, D3 Bio (Wuxi) Co. Ltd., Shanghai, China (Mainland).

C065: *Hematopoietic Progenitor Kinase 1 (HPK1) inhibition enhances antibody secretion, pro-inflammatory cytokine production and proliferation of primary human B cells*. David Ciccone, Nimbus Therapeutics, Boston, MA United States.

C066: *Update on the phase 1 trial of Nelmastobart in patients with advanced solid tumors*. Stephen S. Yoo, STCube, Inc, Seoul, Korea, Republic of.

C067: *Patient-reported baseline symptomatic adverse events in early-phase trials of combination treatments with immune checkpoint blockade, and their association with concurrent global health status, health utilities and clinical factors*. Goldy C. George, The University of Texas MD Anderson Cancer Center, Pearland, TX United States.

C068: *Factors associated with primary resistance to immune checkpoint blockade in early phase clinical trials*. François-Xavier Danlos, Gustave Roussy Institut, Villejuif, France.

C069: *Toripalimab an anti-PD-1 antibody that demonstrates potent T cell activation and enhanced clinical efficacy irrespective of PD-L1 status*. Xiaoguang Wang, Coherus Biosciences, Redwood, CA United States.

C071: *HBI-2375, a selective inhibitor of MLL1-WDR5 interaction, possesses desirable preclinical characteristics in solid tumors in combination with checkpoint inhibitors and also in leukemias in the future clinical investigations*. Farbod Shojaei, HUYABIO International, San Diego, CA United States.

C072: *Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer*. Willemijn Vader, VitroScan, Leiden, Netherlands.

C073: *Single-cell spatial analysis reveals microenvironmental features that contribute to immune discrepancies between adult and pediatric nasopharyngeal carcinomas*. Lanqi Gong, National Cancer Institute, Bethesda, MD United States.

C074: *VPS34 inhibition delays activation-induced STING degradation to prolong STING signaling and improve anti-tumor efficacy in preclinical models*. Madhumita Bogdan, Deciphera Pharmaceuticals, Waltham, MA United States.

C075: *A first-in-class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade*. Jun Gyu Kim, Research Institute, Dong-A ST Co., Ltd., Yongin-si, Korea, Republic of.

C076: *Evidence of TCR and BCR clonal dynamics with enitociclib monotherapy in patients with MYC+ non-Hodgkin lymphoma (NHL)*. Melanie M. Frigault, Vincerx Pharma, Inc., Palo Alto, CA United States.

C077: *STC-15, a small molecule inhibitor of the RNA methyltransferase METTL3, activates anti-tumor immunity and reshapes the tumor microenvironment*. Yaara Ofir-Rosenfeld, Storm Therapeutics Ltd, Cambridge, United Kingdom.

C078: *Pembrolizumab response in melanoma patients: An analysis of the tumor microenvironment*. Anna Juncker-Jensen, NeoGenomics Laboratories, Aliso Viejo, CA United States.

C079: *Comprehensive immunophenotypic profiling sheds light on the dynamic interplay between immune cells in the 4T1 breast cancer model upon anti-PD1 and anti-CTLA4 immunotherapy*. Martin Lange, NUVISAN ICB GmbH, Berlin, Germany.

C080: *Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor immune response*. Yogev Sela, Beyond cancer, Rehovot, Israel.

C081: *Novel and selective inhibitors of KRAS^{G12V}*. Uday Kumar Surampudi, VRise Therpaeutics,Inc., Cambridge, MA United States.

C082: *SCD1 is a potent therapeutic target in MYC-amplified group 3 medulloblastoma*. Stefan Custers, McMaster University, Hamilton, ON Canada.

C083: *HDAC6 inhibition increases proteasome activity and modulates the myeloma immunopeptidome to promote cytotoxic T-cell activity*. James J. Driscoll, University Hospitals Cleveland, Cleveland, OH United States.

C084: *Metabolomic profiling identifies molecular modifiers contributing to proteasome inhibitor resistance in multiple myeloma*. Snehal M. Gaikwad, LCBG, CCR, NCI, NIH, Bethesda, MD United States.

C085: *OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC*. Bernice Matusow, Opna Bio, LLC, South San Francisco, CA United States.

C086: *NP1867, a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2, functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples*. Julian Blagg, NeoPhore Ltd, Cambridge, United Kingdom.

C087: *DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer*. Jennifer Castro, Accent Therapeutics, Lexington, MA United States.

C089: *PRMT5 as a novel druggable vulnerability for EWSR1-ATF1-driven clear cell sarcoma*. Bingbing X. Li, Oregon Health & Science University, Portland, OR United States.

C091: *Liquiritigenin, an estrogen receptor beta agonist, enhances cholesterol biosynthesis inhibitor RO 48-8071-induced growth inhibition of ovarian cancer cells*. Salman Hyder, University of Missouri, Columbia, MO United States.

C092: *PRMT1 promotes pancreatic cancer development and resistance to chemotherapy*. Bomin Ku, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea, Republic of.

C093: *Unlocking the Potential of Metformin: Revealing its Impact on Colorectal Cancer Cells at a Molecular Level*. Georges Nemer, Hamad bin Khalifa University, Doha, Qatar.

C094: *Blocking flotillin-1 palmitoylation abrogates TNBC tumor growth and metastasis*. Bryan McClellan, University of Texas at Austin, Austin, TX United States.

C095: *The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia*. Richard B. Lock, Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia.

C096: *Targeting the p53 pathway to treat pediatric Malignant Rhabdoid and Atypical Teratoid Rhabdoid Tumors*. Alaa Refaat, St Jude Children's Research Hospital, Memphis, TN United States.

C097: *Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma*. Sheila Singh, McMaster University, Hamilton, ON Canada.

C098: *Targeting high-expression LGR5 by an R-spondin-based peptibody-drug conjugate is efficacious against neuroblastoma*. Yukimatsu Toh, The Brown Foundation Institute of Molecular Medicine, Center for Translational Cancer Research, University of Texas Health Science Center at Houston, Houston, TX United States.

C099: *Establishment and characterization of an NUP98-KDM5A-driven AML XPDX model*. Armando Diaz III, XenoSTART, San Antonio, TX United States.

C100: *First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer*. Hirva Mamdani, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI United States.

C101: *Preclinical and clinical pharmacokinetics (PK) of NBF-006, a novel siRNA inhibitor of glutathione-s-transferase P (GSTP) encapsulated in a lipid nanoparticle (LNP), for treatment of advanced non-small cell lung cancer (NSCLC)*. Michael Hall, Nitto BioPharma, Inc., San Diego, CA United States.

C102: *mRNA-mediated restoration of BRCA-1 tumor suppressor function prevents tumor growth and reverses resistance to PARP inhibitors in triple-negative breast cancers*. Gilles Divita, DIVINCELL, NIMES, France.

C103: *Preclinical and clinical safety and tolerability evaluation of NBF-006, a novel siRNA inhibitor of glutathione-s-transferase P(GSTP) encapsulated in a lipid nanoparticle (LNP) for treatment of advanced non-small cell lung cancer (NSCLC)*. Jian Liu, Nitto BioPharma, Inc., San Diego, CA United States.

C104: *Targeted epigenomic inhibition of MYC enhances responses to immune checkpoint and EGFR inhibitors in preclinical models of NSCLC*. Defne Yarar, Omega Therapeutics, Cambridge, MA United States.

C105: *A Systematic Evaluation of the Therapeutic Potential of Base Editing in Cancer Prevention and Treatment*. Rona Merdler-Rabinowicz, Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD United States.

C106: *Identification of nucleic acid drug candidates against mesenchymal transition and its application to breast cancer and glioblastoma cells*. Kiyotsugu Yoshikawa, Doshisha Women's College of Liberal Arts, Kyotanabe, Kyoto, Japan.

C107: *INTASYL™ self-delivering RNAi therapeutic targeting BRD4 elicits on-target apoptosis of human tumor cells*. Andrew Boone, Phio Pharmaceuticals, Marlborough, MA United States.

C108: *Enhanced growth inhibition in lung cancer cells through NBF-006 combination therapy with chemotherapy or KRAS inhibitors*. Cima Cina, Nitto BioPharma, Inc., San Diego, CA United States.

C109: *INTASYL™ PH-894 self-delivering RNAi targeting BRD4 enhances the antigenicity of melanoma cells through MART-1 upregulation*. Brianna Rivest, Phio Pharmaceutical, Marlborough, MA United States.

C110: *miR195 - a potential therapeutic molecule for breast Cancer: Present and Future*. Neeru Saini, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.

C111: *A Novel Human Monoclonal Antibody Targeting Active ADAM10 Demonstrates Anti-Tumor Effects in Colorectal Cancer*. Prem Premsrirut, Mirimus Inc. and Department of Cell Biology, SUNY Downstate Medical Center, Brooklyn, NY United States.

C112: *L1CAM targeting antibody-based therapy as a novel approach for L1CAM positive lymphomas*. Giulio Sartori, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C113: *Discovery of a novel auristatin antibody drug conjugate drug linker with equal efficacy and reduced bone marrow toxicity compared to vedotin*. Noah A. Bindman, Seagen, Bothell, WA United States.

C114: *Dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)*. Jin-Ji Yang, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (Mainland).

C115: *Preclinical characterization of STRO-002, a clinical-stage anti-FolRα antibody-drug conjugate*. Robert Yuan, Sutro Biopharma, South San Francisco, CA United States.

C116: *Impact of human iPSC-derived MSC secretome in modulating radiation induced inflammation and brain vascular endothelial cell damage*. Kshama Gupta, Mayo Clinic, Jacksonville, FL United States.

C117: *Preclinical Characterization of Allogeneic CAR γδ T Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope on PSMA*. Nitya S. Ramadoss, Adicet Bio, Inc., Redwood City, CA United States.

C118: *Design of Programmable Peptide-Guided Oncoprotein Degraders via Generative Language Models*. Pranam Chatterjee, Duke University, Durham, NC United States.

C119: *Combining forces: Integrating engineered bacterial therapeutics with targeted therapies for advanced-stage non-small cell lung cancer*. Dhruba Deb, Columbia University, New York, NY United States.

C120: *Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines*. Hae Min Hwang, Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of.

C121: *Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC*. Rachael Brake, Corbus Pharmaceuticals, Norwood, MA United States.

C122: *The impact of the short-chain fatty acids on viability, motility and migration of oral squamous cell carcinoma cell line*. Ariana S. Garcia, UPR Recinto de Mayagüez, San Juan, Puerto Rico.

C123: *Alloferon Inhibits Migration of Pancreatic Cancer by Regulating the Expression of IL-22Rα*. Hyejung Jo, Seoul National University College of Medicine, Seoul, Korea, Republic of.

C124: *Assessment of the anticancer potential of a natural compound euphol in colorectal cancer from in vitro and in vivo mouse models*. Ana Laura Vieira Alves, Barretos Cancer Hospital, Barretos, Brazil.

C125: *Development of attenuated orf virus as a new generation oncolytic viral vector*. Yumiko Yamada, Graduate Institute of Microbiology and Public Health, National Chung Hsing University, Taichung, Taiwan (Greater China).

C126: *Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling of novel covalent Kelch-like ECH-associated protein 1 (KEAP1) activators*. Peter N. Morcos, Bayer, Whippany, NJ United States.

C127: *Discovery of AUR-112, a novel MALT1 protease inhibitor for the treatement of B cell lymphomas*. Dinesh Chikkanna, Aurigene oncology limited, Bangalore, India.

C128: *PT-112, a novel immunogenic cell death inducer, causes ribosomal biogenesis inhibition and organelle stress in cancer cells*. Christina Y. Yim, Promontory Therapeutics Inc., New York, NY United States.

C129: *Development of new increased potency Ref-1/APE1 targeted inhibitors that show promise for clinical applications against solid tumors*. Silpa Gampala, Department of Pediatrics and Herman B Wells Center for Pediatric Research, Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN United States.

C130: *Discovery and characterization of an MTA-cooperative and brain-penetrant PRMT5 inhibitor*. Haiyan Ying, Abbisko Therapeutics, Shanghai, China (Mainland).

C132: *SGN-35T: a novel CD30-directed antibody-drug conjugate for the treatment of lymphomas*. Kevin J Hamblett, Seagen, Inc., Bothell, WA United States.

C133: *BBT-4437, a novel, brain-penetrable, reversible pan-TEAD inhibitor targeting the Hippo signaling pathway in solid tumors*. Leila Revollo, Bridge Biotherapeutics, Inc., Newton, MA United States.

C134: *The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)*. Varsha Ananthapadmanabhan, Dana-Farber Cancer Institute, Boston, MA United States.

C135: *Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers*. Didier Pez, Ryvu Therapeutics S.A, Krakow, Poland.

C136: *VHL, PBRM1, and BAP1 mutation variants and response to first-line therapies in patients with metastatic clear-cell renal cell carcinoma (mRCC)*. Jessica Zhu, University of Colorado Anschutz Medical Campus, Aurora, CO United States.

C137: *Tumor-selective, chaperone-mediated targeting of ERK5 (MAPK7)*. Kevin P. Foley, Ranok Therapeutics, Waltham, MA United States.

C138: *The benefit of Ma recipe, A combination of Chinese herbal medicines for patients with advanced esophageal cancer: A retrospective case report series*. Jiangnan Feng, Tongrun Tang Traditional Chinese medicine clinic, Wuhan, China (Mainland).

C139: *The IRAK4 inhibitor emavusertib (CA-4948) synergizes with second generation BTK inhibitors acalabrutinib and zanubrutinib in MYD88-L265P mutated lymphoma cell lines.* Francesco Bertoni, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C140: *BI 1810631 is a novel EGFR wild-type sparing, HER2-selective small molecule inhibitor that efficiently blocks HER2 mutant-driven lung cancer*. Martin Augsten, Boehringer Ingelheim RCV GmbH Co KG, Vienna, Austria.

C141: *Targeting SHP2-dependent adaptive resistance to BRAF and MEK inhibition in gliomas*. Abiola Abdulrahman Ayanlaja, Johns Hopkins University, Baltimore, MD United States.

C143: *Unveiling Synergistic Interplay between KRAS^{G12C} Inhibitors and the Polyamine Synthesis Inhibitor SAM486 against lung cancer cells: An In Vitro Study*. Rodrigo A. Lopez-Muñoz, Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia, Chile.

C144: *MEN1703/ SEL24, a potent PIM inhibitor, demonstrates promising anti-tumour activity in activated B cell like diffuse large B cell lymphoma, mantle cell lymphoma and marginal zone lymphoma cells*. Afua A. Mensah, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

C145: *ANS014004, a novel small-molecule type II c-Met inhibitor effectively overcomes clinical-resistance MET mutations and exhibits antitumor activity in preclinical models of MET-amplified non-small cell lung cancer (NSCLC) and gastric cancer*. Kevin Schaab, Avistone Biotechnology, Inc., San Diego, CA United States.

C146: *VIC-1911, a selective Aurora kinase A inhibitor, synergizes with sacituzumab govitecan in triple-negative breast cancer*. Jangsoon Lee, University of Hawai'i Cancer Center, Honolulu, HI United States.

C147: *The DNA replication checkpoint inhibitors, ATRN-1051 (WEE1i) and ATRN-119 (ATRi), are potentially well tolerated and effective cancer treatments*. Eric J. Brown, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA United States.

C148: *Type II ROS1 inhibitors and their liability on ROS1 rearranged non-small cell lung cancer with L2086F mutation*. Rajat Thawani, Oregon Health & Science University, Portland, OR United States.

C149: *Efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2*. Stephen V. Liu, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC United States.

C150: *Targeted Inhibition of Homologous Recombination and Nonhomologous End Joining in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence*. Ivana Barravecchia, University of Michigan, Ann Arbor, MI United States.

C151: *BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets*. Xiuning Le, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

C152: *Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious 'de-hinging' to improve tolerability*. Timothy P.S. Perera, DeuterOncology NV, Liege, Belgium.

C153: *Rare BRAF mutations in menlanoma and beyond: Rationalizing the afficacy of B-raf inhibitors via HPC-based in silico/in vitro investigations*. Sabrina Pricl, University of Trieste, Trieste, Italy.

C154: *Investigation of indole-based molecules as a new class of TLK1 inhibitors in prostate cancer therapy*. Delna Johnson, Indian Institute of Technology, Gandhinagar, Gandhinagar, India.

C155: *In-vitro Multicellular 3D-Spheroid Model Demonstrates the Synergistic Effect of 2-Domain Soluble FMS-Like Tyrosine Kinase-1 (2d-sFlt-1) for Breast Cancer Targeted Therapies*. Adel Zaid I. Mutahar, Molecular Oncology Lab., Department of Studies in Biotechnology, University of Mysore, Mysore, India.

C156: *Dasatinib targets an upregulated SRC family kinase gene in extramedullary leukemia, improving prognosis in these patients*. Isabel Cunningham, Columbia University, New York, NY United States.

C157: *Targeting PIK3CA and CDKN2A alterations in Esophageal Adenocarcinoma with Alpelisib and Palbociclib*. Naryan Rustgi, Columbia University, New York, NY United States.

C158: *Predicting TKI responses in PDGFRA-mutant gastrointestinal stromal tumor*. Homma M. Khosroyani, Oregon Health and Science University, Portland, OR United States.

C159: *ALK Signaling Primes the DNA Damage Response Allowing Exploitation of ATR inhibition in ALK-driven Neuroblastoma*. Ruth H. Palmer, University of Gothenburg, Gothenburg, Sweden.

C160: *HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment*. Jia Hu, HUTCHMED Limited, Shanghai, China (Mainland).

C161: *Identification of a reversible selective FGFR2 clinical development candidate with potency against gatekeeper and molecular brake mutations*. John Fischer, Cogent Biosciences, Waltham, MA United States.

C162: *Assessment of the potential for QTc prolongation by the investigational ATR inhibitor tuvusertib in patients with advanced solid tumors using integrated nonclinical and clinical assessments*. Jatinder Kaur Mukker, EMD Serono, Billerica, MA United States.

C163: *KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition*. Elia Aguado-Fraile, Repare Therapeutics, Cambridge, MA United States.

C164: *A phase 1 dose-escalation study of PRT2527, a cyclin-dependent kinase 9 (CDK9) inhibitor, in adult patients with advanced solid tumors: an updated analysis*. Neelesh Sharma, Prelude Therapeutics Incorporated, Wilmington, DE United States.

C165: *Zurletrectinib, a next-generation TRK inhibitor shows strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation drugs*. Paola Roa, University of Miami, Miami, FL United States.

C166: *Development of BLX-3030, a Potent and Selective Inhibitor of CDK9 for the Treatment of N-MYC Driven NeuroEndocrine Prostate Cancers (NEPC)*. Hariprasad Vankayalapati, Biolexis Therapeutics, Inc., American Fork, UT United States.

C167: *An SN38 dendrimer nanoparticle, DEP irinotecan (SN38-SPL9111), demonstrates efficacy in mouse models of gastrointestinal cancer and augments anti-tumor effects of immune checkpoint blockade and PARP inhibition*. Jeremy R.A. Paull, Starpharma Pty Ltd, Melbourne, Australia.

C168: *Prognostic value of tumor microenvironment (TME) features in advanced, EGFR-mutant non-small cell lung cancer (NSCLC)*. Lodovica Zullo, Institut Gustave Roussy, Villejuif, France.

C169: *AVA3996, a novel pre|CISION™ medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage to elicit tumor cell kill*. David Jones, Avacta Life Sciences, London, United Kingdom.

C171: *Immune desert microenvironment is associated with poor outcome in Wilms tumors*. Xiaoping Su, UT MD Anderson Cancer Center, Houston, TX United States.

C172: *PTX3 blockade restores anti-tumor immunity through suppressing M2-like macrophages phenotypes in colon cancer*. Feng-Wei Chen, Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan (Greater China).

C173: *Negative selection of ligand-receptor interactions mediating lymphocyte infiltration confers melanoma resistance to Immune Checkpoint Blockade therapy by turning hot tumors to cold*. Sahil Sahni, National Cancer Institute, Bethesda, MD United States.

C174: *MerTK as a putative biomarker for treatment response in triple negative breast cancer*. Bridget E. Mehall, University of Wisconsin, Madison, WI United States.

C175: *The potential effect of KRAS inhibitors on tumor microenvironments*. Noritaka Tanaka, Kansai Medical University, Hirakata, Japan.